NASDAQ$DVAX
Dynavax Technologies Corp · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported record revenue driven by CpG 1018 adjuvant sales and increased HEPLISAV-B sales.
Dynavax reported record total revenue for 2021, driven by significant growth in CpG 1018 adjuvant and HEPLISAV-B sales. The company achieved its first profitable year and ended the year with a strong cash position, enabling investments in its pipeline.
- Total revenues for the fourth quarter of 2021 were $195.1 million, compared to $19.6 million for 2020.
- HEPLISAV-B product revenue, net was $17.2 million for the fourth quarter of 2021 compared to $11.5 million for the fourth quarter of 2020.
- CpG 1018 product revenue, net was $177.4 million in the fourth quarter of 2021 compared to $1.6 million in the fourth quarter of 2020.
- GAAP net income was $99.8 million in the fourth quarter of 2021, compared to GAAP net loss in the fourth quarter of $15.5 million in the fourth quarter of 2020.
Headline financials
Revenue & EPS history
Dynavax · Revenue · Quarterly
$195M
Revenue by segment
Dynavax · $69.5M total across 2 segments · Q3 2023
- HEPLISAV-B Net Product Revenue$62.3M+66.1%89.6%
- Other Revenue$7.2M—10.4%
Forward guidance
In 2022, Dynavax anticipates CpG 1018 adjuvant net product revenues of at least $550 million, SG&A expenses between approximately $120 - $140 million, Research and development expenses to be between approximately $55 - $70 million and interest expense of approximately $7 million.
Tailwinds
- Full year CpG 1018 adjuvant net product revenues of at least $550 million
- Gross margin of approximately 50% for CpG 1018 adjuvant net product revenues
Headwinds
- Selling, general and administrative expenses to be between approximately $120 - $140 million
- Research and development expenses to be between approximately $55 - $70 million
- Interest expense of approximately $7 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2021
-0.6%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+0.9%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+18.1%
Q1 2019
Best reaction
-29.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.5% | +2.4% | -1.0% | |
| Q2 2025 | -6.7% | -2.2% | -9.0% | |
| Q1 2025 | -11.0% | -9.6% | -6.1% | |
| Q4 2024 | +0.0% | +2.5% | +3.6% | |
| Q3 2024 | +5.9% | +9.6% | +4.5% | |
| Q2 2024 | +6.8% | +10.1% | +7.2% | |
| Q1 2024 | -6.4% | -6.2% | +2.6% | |
| Q4 2023 | +2.3% | +4.3% | -1.4% | |
| Q3 2023 | +0.9% | -5.5% | -2.8% | |
| Q2 2023 | +7.1% | +10.0% | +7.4% | |
| Q1 2023 | +4.8% | +7.0% | +9.0% | |
| Q4 2022 | -5.0% | -5.5% | -9.4% | |
| Q3 2022 | +11.6% | +10.3% | +12.6% | |
| Q2 2022 | +17.8% | +20.7% | -20.6% | |
| Q1 2022 | -4.3% | -12.0% | +29.7% | |
| Q4 2021 | -2.2% | -16.1% | -11.8% | |
| Q3 2021 | -22.8% | — | — | |
| Q2 2021 | +6.1% | — | — | |
| Q1 2021 | +9.7% | — | — | |
| Q4 2020 | -6.7% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | -13.5% | — | — | |
| Q1 2020 | -8.8% | — | — | |
| Q4 2019 | -29.1% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +5.2% | — | — | |
| Q1 2019 | +18.1% | — | — | |
| Q4 2018 | -7.8% | — | — | |
| Q3 2018 | +2.2% | — | — | |
| Q2 2018 | +5.8% | — | — | |
| Q1 2018 | -5.0% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +6.4% | — | — | |
| Q2 2017 | +12.7% | — | — | |
| Q1 2017 | +0.9% | — | — | |
| Q4 2016 | -2.5% | — | — | |
| Q3 2016 | +6.7% | — | — | |
| Q2 2016 | -2.3% | — | — | |
| Q1 2016 | +8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +10.8% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -9.2% | — | — | |
| Q1 2014 | -3.9% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | +4.5% | — | — | |
| Q2 2013 | +2.4% | — | — | |
| Q1 2013 | -5.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | -3.6% | — | — | |
| Q4 2011 | +3.1% | — | — | |
| Q3 2011 | -14.0% | — | — | |
| Q2 2011 | -14.6% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -8.1% | — | — | |
| Q1 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro